他汀类药物使用与新发外周动脉疾病的关联:基于多种族动脉粥样硬化研究,按种族、年龄和抑郁状态分析
基于多种族动脉粥样硬化研究(MESA)4,210名参与者(随访平均11.3年),他汀治疗组新发外周动脉疾病风险低于未治疗组(HR=0.45,95%CI:0.33-0.62)。种族和抑郁状态未显著修饰该关联,但黑人美国种族风险较低(HR=0.70,95%CI:0.58-0.84)。年龄分层中45-74岁他汀使用仍显著,75-84岁不显著。
要点
- 他汀治疗与新发PAD风险降低相关(HR=0.45,95%CI:0.33-0.62)。
- 抑郁状态和种族未显著修饰他汀使用与新发PAD的关联。
- 75-84岁人群他汀使用与新发PAD关联不显著,45-74岁显著。
核心结论
- 他汀使用与75岁以下人群新发PAD风险降低相关;种族和抑郁未显著修饰该关联,但黑人美国种族新发PAD风险较低;他汀获益在75岁以上人群可能减弱;抑郁者他汀使用可能不受影响。
研究设计与样本
- 基于多种族动脉粥样硬化研究(MESA)第1次(2000年)至第6次(2020年)随访数据,纳入在第1、3、5次随访有三次踝臂指数(ABI)测量的参与者。
- 采用倾向性评分匹配平衡他汀治疗组与未治疗组,使用Cox比例风险回归分析时间依赖性他汀使用与新发PAD的关系,并按种族、抑郁状态和年龄分层。
主要发现
- 最终匹配分析队列共4,210名参与者,平均随访11.3年(SD=5.7)期间发生810例(19.3%)新发PAD。
- 他汀治疗组平均随访12.5年(SD=5.6)发生281例(13.4%)新发PAD,未治疗组平均随访10.1年(SD=5.5)发生531例(25.2%)(P<0.001)。
- 他汀治疗组较未治疗组新发PAD风险降低(HR=0.45,95%CI:0.33-0.62),随访跨度18.5年。
- 黑人美国种族较非西班牙裔白人新发PAD风险降低约30%(HR=0.70,95%CI:0.58-0.84)。
- 年龄分层模型:45-54岁他汀使用显著(HR=0.45,95%CI:0.33-0.63),55-64岁显著(HR=0.61,95%CI:0.46-0.79),65-74岁显著(HR=0.61,95%CI:0.48-0.78),75-84岁不显著。
关键数值与推荐
- 新发PAD定义为:1)新发下肢截肢或血运重建,或2)ABI小于0.90且随访期间ABI下降大于0.15。
- 他汀使用记录于新发PAD诊断前一次研究访视;抑郁症状在第1次、第3次和第5次检查时测量。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Peripheral artery disease (PAD) is associated with high morbidity and mortality and has been commonly described as a coronary heart disease equivalent. Statin medications are recommended for primary prevention of atherosclerotic cardiovascular disease (CVD) among other indications. Therefore, understanding the longitudinal relationship of incident PAD is necessary to inform future research on how to prevent the disease. Depression complicates CVD patients' ability to properly adhere to their medications, yet the effect of depression on the relationship between statin use and incident PAD is understudied. People with PAD have a higher incidence of depressive symptoms than people without PAD. Black American and Hispanic populations are disproportionately affected by both PAD and depression yet research on the modifying effect of either race or depression on the relationship between statin use and onset of PAD is minimal. While statin utilization is highest for ages 75-84 years, there is minimal evidence of favorable risk-benefit balance. Consequently, in this project, we examined the relationship between statin use and incident PAD and whether this relationship is modified by race/ethnicity, depressive symptoms, or age. METHODS: We used data on participants from the Multi-Ethnic Study of Atherosclerosis from visit 1 (2000) through study visit 6 (2020) who had three separate measurements of the ankle-brachial index (ABI) taken at visit 1, visit 3, and visit 5. Incident PAD was defined as 1) incident lower extremity amputation or revascularization or 2) ABI less than 0.90 coupled with ABI decrease greater than 0.15 over the follow-up period. Statin use was noted on the study visit prior to incident PAD diagnosis while depressive symptoms were measured at exam 1, visit 3, and visit 5. Propensity score matching was implemented to create balance between the participants in the two treatment groups, that is, statin-treated and statin-untreated groups, to reduce the problem of confounding by indication. Propensity scores were calculated using multivariate logistic regression model to estimate the probability of receiving statin treatment. We used Cox proportional hazards regression to investigate the relationship between time-dependent statin use as well as other risk factors with incident PAD, overall and stratified by 1) race, 2) depression status, and 3) age. RESULTS: A total of 4,210 participants were included in the final matched analytic cohort. There were 810 incident cases (19.3%) of PAD that occurred over an average (mean) of 11.3 years (SD = 5.7) of follow-up time. In the statin-treated group, and with an average follow-up time of 12.5 years (SD = 5.6), there were 281 cases (13.4%) of incident PAD with the average follow-up time of 10.1 years (SD = 5.5), whereas in the statin-untreated group, there were 531 cases (25.2%) (P < 0.001). Results demonstrate a lower risk of PAD event in the statin-treated group compared to the untreated group (hazard ratio [HR] = 0.45, 95% confidence interval [CI]: 0.33-0.62) over the span of 18.5 years. The interactions between 1) depression and 2) race with statin use for incident PAD were not significant. However, other risk factors which were significant included Black American race that had approximately 30% lower hazard of PAD compared to non-Hispanic White (HR = 0.70, 95% CI: 0.58-0.84); age-stratified models were also fitted, and stain use was still a significant treatment factor for ages 45-54 (HR = 0.45, 95% CI: 0.33-0.63), 55-64 (HR = 0.61, 95% CI: 0.46-0.79), and 65-74 years (HR = 0.61, 95% CI: 0.48-0.78) but not for ages 75-84 years. CONCLUSIONS: Statin use was associated with a decreased risk of incident PAD for those under the age of 75 years. Neither race nor depression significantly modified the relationship between statin use and incident PAD; however, the risk of incident PAD was lower among Black Americans. These findings highlight that the benefit of statin may wane for those over the age of 75 years. Findings also suggest that statin use may not be compromised in those living with depression.
引用
- Bolden DM, Wogu AF, Peterson PN, et al. Association between Statin use and Incident Peripheral Artery Disease According to Race, Age, and Presence of Depression in the Multi-Ethnic Study of Atherosclerosis. Ann Vasc Surg. 2024. PMID: 38309426. doi:10.1016/j.avsg.2023.11.030
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。